Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks
Dompé U.S. Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act.
What happened
Dompé U.S. Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act.
Why it matters
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Affected entities
View evidence
1 reports · 1 original report · 1 independent
- U.S. Department of JusticePrimary source · Supports · EN · 100%Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks ↗
Claims
- Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks Observed
Conflicts
No material conflict detected in the available evidence.
Timeline
- First reported
Market move following event
Market reaction is not yet available for this asset and time window.